title: Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4).
abstract: A patient with a CD4+ refractory peripheral T-cell lymphoma (PTL), subtype angioimmunoblastic T-cell lymphoma (AILD), was treated with a human monoclonal anti-CD4 antibody (HuMax-CD4) iv once weekly for 10 wk. Early during treatment all palpable enlarged lymph nodes disappeared. A decline of normal CD4+ T-cells in the blood mirrored the treatment effect. Shortly after stopping treatment the patient relapsed with new enlarged lymph nodes. This time no antitumor effect was seen when HuMax-CD4 treatment was reinstituted. No severe side effects were observed during the antibody treatment. This case report is the first describing that HuMax-CD4 has antilymphoma activity in PTL and is an interesting drug to study further in patients with CD4+ PTL.
authors.affiliation: Department of Oncology, Akademiska sjukhuset, Uppsala, Sweden. hans.hagberg@akademiska.se
authors.forename: H
authors.initials: H
authors.lastname: Hagberg
authors.forename: M
authors.initials: M
authors.lastname: Pettersson
authors.forename: T
authors.initials: T
authors.lastname: Bjerner
authors.forename: G
authors.initials: G
authors.lastname: Enblad
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D015704:CD4 Antigens / Q000276:immunology*; D003131:Combined Modality Therapy; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D007167:Immunotherapy; D008198:Lymph Nodes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D016411:Lymphoma, T-Cell, Peripheral / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000628:therapy
chemical_list: D000911:Antibodies, Monoclonal; D015704:CD4 Antigens